Manon A.
- Country
- France
- Department
- Service d'Hépatologie
Research Overview
- Phase 1b Study of NP137 with Atezolizumab-Bevacizumab in First-Line Treatment of Unresectable Hepatocellular Carcinoma
- Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carcinoma, a phase 2b randomized trial. ABE-LIVER
- PRODIGE 81-FFCD 2101-TRIPLET: Randomized, open-label, phase II-III study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patients with hepatocellular carcinoma receiving first-line systemic therapy
Data & Insights
Has run more than one trial at 47 of 161 partner sites.
Specializations
Liver Cancer Management
The investigator specializes in treating hepatocellular carcinoma (HCC) through various therapeutic approaches, with particular emphasis on both early-stage and advanced disease management.
- BCLC A HCC Treatment
- Locoregional Therapy
- Post-Transplant HCC Management
Their research encompasses curative interventions for early-stage disease and innovative approaches for unresectable cases.
Interventional Oncology
Focuses on minimally invasive therapeutic procedures for liver cancer, particularly percutaneous ablation and transarterial chemoembolization (TACE).
- Ablative Procedures
- TACE Optimization
- Combined Treatment Strategies
Expertise includes developing integrated approaches combining local and systemic treatments.
Immunotherapy Innovation
Leading research in novel immunotherapeutic approaches for liver cancer, including combination strategies with established treatments.
- Checkpoint Inhibitor Therapy
- Anti-angiogenic Combinations
- Targeted Immunotherapy
Investigates innovative protocols incorporating immunotherapy with conventional treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.